Predictive factors for efficacy and adverse reactions of ziprasidone in schizophrenia patients

doi:10.3969/j.issn.1006-7795.2016.02.011

Abstract

Abstract: Objective To analyze factors related to efficacy of ziprasidone and extrapyramidal symptom (EPS) in 70 schizophrenia patients treated with ziprasidone. Methods Multi linear Logistic regression was used to analyze factors related to efficacy of the treatment and extrapyramidal symptom in 70 schizophrenia patients treated with ziprasidone.Results Significant episodes of the disease were the predictor for the good effect of ziprasidone(β=-0.496, P=0.000). Previous history with acute dysmyotonia and Parkinson syndrome, prominent positive symptom, were the predictor for acute dysmyotonia and Parkinson syndrome(β=-0.634, 0.332 respectively, P=0.000 for both). Previous history of akathisia, prominent positive symptom, and relapse time of disease were the predictor for akathisia(β=0.633, 0.136 respectively, P=0.000, 0.034 respectively), prominent negative symptom and duration of disease were the protective factors for akathisia(β=-0.310, -0.181 respectively, P=0.000, 0.024 respectively).Conclusion Schizophrenia patients with few relapses of disease will demonstrate good therapeutic effect when treated with ziprasidone. Schizophrenia patients with previous history of extrapyramidal symptom, or with fewer relapses of disease may show higher occurrence of EPS; patients with prominent negative symptom, long duration of disease may predict lower occurrence of akathisia. Patients with prominent positive symptom may predict higher occurrence of acute dysmyotonia and Parkinson syndrome.

Key words: schizophrenia, ziprasidone, effect, extrapyramidal symptom, predictive factors

CLC Number:

R749.05

Zhu Hong, Jia Hongxiao, Yan Aiguo, Zhi Lihua. Predictive factors for efficacy and adverse reactions of ziprasidone in schizophrenia patients[J]. Journal of Capital Medical University, 2016, 37(2): 164-167.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.02.011

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I2/164

References

[1] American Psychiatric Association. Diagnostic and statistic manual of mental disorders[M].Washington D C:American Psychiatric Press, Inc., 2000.
[2] 易正辉,卢卫红,朱丽萍,等.第二代抗精神病药的进一步研究(三)利培酮早期反应预测后期疗效的研究[J].临床精神医学杂志,2004, 14(1):37-38.
[3] 卢晓星.影响精神分裂症患者抗精神病药物治疗效果的因素分析[J].重庆医学,2013,42(21):2473-2475.
[4] Lewis D A, Lieberman J A. Catching up on schizophrenia:natural history and neurobiology[J]. Neuron, 2000, 28(2):325-334.
[5] Keefe R S, McEvoy J P. Negative symptom and cognitive deficit treatment response in schizophrenia[M]. Washington DC:American Psychiatric Press, Inc., 2001, 163-175.
[6] Takeuchi H, Suzuki T, Bies R R,et al. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia:An analysis of the CATIE data[J]. Schizophr Res, 2013,150(2-3):373-379.
[7] Blaisdell G D. Akathisia:a comprehensive review and treatment summary[J]. Pharmacopsychiatry, 1994, 27(4):139-146.
[8] Lechin F, van der Dijs B.Noradrenergic hypothesis of schizophrenia[J]. Prog Neuro Psychopharmacol & Biological Psychiatry, 2005, 29(5):777-778.
[9] Stahl S M, Shayegan D K.The psychopharmacology of ziprasidone:receptor-binding properties and real-world psychiatric practice[J]. J Clin Psychiatry, 2003, 64 (Suppl 19):6-12.
[10] Comai S, Tau M, Pavlovic Z,et al. The psychopharmacology of aggressive behavior:a translational approach:part 2:clinical studies using atypical antipsychotics, anticonvulsants, and lithium[J]. J Clin Psychopharmacol, 2012,32(2):237-260.
[11] Olié J P, Spina E, Murray S,et al.Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia:results of a 12-week, double-blind study[J]. Int Clin Psychopharmacol, 2006, 21(3):143-151.
[12] Kuepper R, Skinbjerg M, Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited:new insights into topography and course[J]. Handb Exp Pharmacol, 2012(212):1-26.

[1]	Yang Jingxing, Cai Chao, Zhao Yan, Wang Xiangdong, Zhang Luo. Research advances in the anti-inflammatory effects and mechanisms of baicalin in chronic inflammatory diseases of respiratory mucosa [J]. Journal of Capital Medical University, 2022, 43(6): 919-923.
[2]	Yang Zhiyuan, Wu Yuxuan, Qiao Qingyu, Liu Xiaoli. Analyze to mediating effects of recommended popularity in online medical platform [J]. Journal of Capital Medical University, 2022, 43(3): 456-462.
[3]	Lian Siyuan, Wu Han, Han Jinxiang, Xiao Cunli, Ren Yanping, Jin Wenqing, Wang Wen, Ma Xin. Study of related factors on self-report effects of rehabilitation in schizophrenia patients [J]. Journal of Capital Medical University, 2022, 43(2): 233-238.
[4]	Li li, Liu Chaomeng, Ren Yanping, Yang Chunlin, Ma Xin. Research advances of modified electroconvulsive therapy for first-episode schizophrenia [J]. Journal of Capital Medical University, 2022, 43(2): 249-253.
[5]	Guo Chengwei, Zhou Jiaojiao, Feng Yuan, Yang Yunping. A comparative study of self esteem between schizophrenics and normal people [J]. Journal of Capital Medical University, 2022, 43(2): 294-298.
[6]	Zhu Ping, Yu Huan, Fu Limei, Liao Xin, Xiong Mujun, Lei Aming, Zhu Pingan, Liang Xinquan. Clinical analysis of umbilical cord blood transplantation in the treatment of refractory and recurrent acute leukemia [J]. Journal of Capital Medical University, 2021, 42(6): 1041-1045.
[7]	Chen Xi, Ma Denglei, Li Lin. Effects of icariin on the behavioral changes, demyelination and neuroinflammation in mice with cuprizone-induced schizophrenia [J]. Journal of Capital Medical University, 2021, 42(5): 761-767.
[8]	Cui Yuli. Clinical effect of photodynamic therapy combined with liquid nitrogen freezing on the treatment of condyloma acuminatum [J]. Journal of Capital Medical University, 2021, 42(5): 857-861.
[9]	Ning Yanzhe, Zhu Hong, Song Nan, Zheng Sisi, Li Ziyan, Li Jiajia, Ma Rui, Jia Hongxiao. A preliminary study on efficacy for Shi-zhen-an-shen granules on cognitive impairments in prodromal schizophrenia [J]. Journal of Capital Medical University, 2021, 42(3): 404-407.
[10]	Yi Yuwei, Yan Fang, Jin Yuhong, Xiao Cunli. Analysis of influencing factors of risk behaviors of inpatients with schizophrenia [J]. Journal of Capital Medical University, 2021, 42(2): 323-327.
[11]	Sha Sha, Zhao Xixi, Han Chuanliang, Peng Xing, Zhang Pei, Dong Wen, Yin Jingjing, Wang Changming. Correlation between alpha activity and cognitive in resting electroencephalogram of schizophrenia [J]. Journal of Capital Medical University, 2021, 42(1): 117-124.
[12]	Zhang Ying, Wang Ruomei, Li Gang. Cognitive function, emotion management and its influencing factors in stable schizophrenia [J]. Journal of Capital Medical University, 2021, 42(1): 143-147.
[13]	Yan Dan. Clinical bio-characteristic profiling: Evaluation of quality control and rational drug use of Chinese materia medica——Professor Yan Dan [J]. Journal of Capital Medical University, 2020, 41(5): 773-777.
[14]	Fang Da, Zhao Qian, Du Ning, Zhao Liying, Ma Liang, Cui Shichang. Analysis of radiation dose of radiology intervention for patients with liver cancer [J]. Journal of Capital Medical University, 2020, 41(3): 454-457.
[15]	Yu Ying, Gao Feng, Zhang Jie. Study on the relationship between the changes of microbiota and therapeutic effect in patients with reflux esophagitis [J]. Journal of Capital Medical University, 2020, 41(2): 243-248.